Your browser doesn't support javascript.
loading
Detection of soluble ERBB2 in breast cancer cell lysates using a combined label-free/fluorescence platform based on Bloch surface waves.
Sinibaldi, Alberto; Sampaoli, Camilla; Danz, Norbert; Munzert, Peter; Sibilio, Leonardo; Sonntag, Frank; Occhicone, Agostino; Falvo, Elisabetta; Tremante, Elisa; Giacomini, Patrizio; Michelotti, Francesco.
Afiliación
  • Sinibaldi A; Department of Basic and Applied Science for Engineering, Sapienza University of Rome, Via A. Scarpa 16, 00161 Rome, Italy. Electronic address: alberto.sinibaldi@uniroma1.it.
  • Sampaoli C; Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.
  • Danz N; Fraunhofer Institute for Applied Optics and Precision Engineering IOF, Albert-Einstein-Str. 7, 07745 Jena, Germany.
  • Munzert P; Fraunhofer Institute for Applied Optics and Precision Engineering IOF, Albert-Einstein-Str. 7, 07745 Jena, Germany.
  • Sibilio L; IBI, Istituto Biochimico Italiano Giovanni Lorenzini Spa, Via Fossignano 2, 04011 Aprilia, Italy.
  • Sonntag F; Fraunhofer Institute for Material and Beam Technology IWS, Winterbergstr. 28, 01277 Dresden, Germany.
  • Occhicone A; Department of Basic and Applied Science for Engineering, Sapienza University of Rome, Via A. Scarpa 16, 00161 Rome, Italy.
  • Falvo E; Institute of Molecular Biology and Pathology, National Research Council, P.le Aldo Moro 5, 00185 Rome, Italy.
  • Tremante E; Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.
  • Giacomini P; Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.
  • Michelotti F; Department of Basic and Applied Science for Engineering, Sapienza University of Rome, Via A. Scarpa 16, 00161 Rome, Italy.
Biosens Bioelectron ; 92: 125-130, 2017 Jun 15.
Article en En | MEDLINE | ID: mdl-28209555
We report on the use of one-dimensional photonic crystals to detect clinically relevant concentrations of ERBB2/neu/Her2 in cell lysates. ERBB2 is a pivotal breast cancer biomarker and targetable oncogenic driver associated with aggressive breast cancer subtypes. To quantitate soluble ERBB2, we developed an optical platform that combines label-free and fluorescence detection modes. Such platform makes use of a sandwich assay in which the one-dimensional photonic crystals sustaining Bloch surface waves are tailored with a monoclonal antibody for highly specific biological recognition (BSW biochip). In a second step, a second antibody to ERBB2 quantitatively detects the bound analyte. The strategy of the present approach takes advantage of the combination of label-free and fluorescence techniques, making bio-recognition more robust and sensitive. In the fluorescence operation mode, the platform can attain the limit of detection 0.3ng/mL (1.5pM) for ERBB2 in cell lysates. Such resolution meets the international guidelines and recommendations (15ng/mL) for diagnostic ERBB2 assays that in the future may help to more precisely assign therapies counteracting cancer cell proliferation and metastatic spread.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mama / Neoplasias de la Mama / Técnicas Biosensibles / Receptor ErbB-2 Tipo de estudio: Diagnostic_studies / Evaluation_studies / Guideline Límite: Female / Humans Idioma: En Revista: Biosens Bioelectron Asunto de la revista: BIOTECNOLOGIA Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mama / Neoplasias de la Mama / Técnicas Biosensibles / Receptor ErbB-2 Tipo de estudio: Diagnostic_studies / Evaluation_studies / Guideline Límite: Female / Humans Idioma: En Revista: Biosens Bioelectron Asunto de la revista: BIOTECNOLOGIA Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido